Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3978_Библиотеки_им_академика_М_И_Перельмана
.pdf
436
Lorazepam , 62
Lowell, J.A. , 354
Low-molecular-weight heparin (LMWH) ,
164, 167, 183, 184, 188
Luyt, C.E. , 218
M
Magnesium sulfate (MgSO
4
) , 57, 237,
265, 275
Magnetic resonance angiography (MRA) , 150
Martin-Stone, S. , 161–192
McIlroy, D.R. , 333
Mean arterial pressure (MAP) , 114, 199, 297
IBP monitoring , 80
oscillometric technique , 79
Medicare Provider Analysis and Review
(MEDPAR) Database , 422
Metabolic acidosis , 404–407
Metabolic alkalosis , 407–409
Midazolam , 63
Milrinone , 48, 49, 202
Minimized extracorporeal circulation
(MECC) , 300–301
Minnesota Sedation Assessment Tool
(MSAT) , 59, 132
Modifi ed Beer-Lambert Law , 142
Moore, F.D. , 355
Motor Activity Assessment Scale
(MAAS) , 132
Motor-evoked potential (MEP) , 141
Murkin, J.M. , 143
Myosin-binding protein C (MYBPC) ,
19, 21, 24
N
Nationwide Inpatient Sample (NIS) , 423
Natural colloids. See Albumin (HA)
Near-infrared spectroscopy (NIRS) ,
131, 142, 253
Needle through catheter technique , 82, 83
Neuraxial blocks
spinal (intrathecal) analgesia , 280–281
TEA , 281–283
thoracic paravertebral block , 278–280
Neuromuscular blocking agents (NMBAs) , 65
adjunct therapy , 66
TOF monitoring , 64, 66
toxicity of , 64
New Sheffi eld Sedation Scale (Sheffi eld) , 132
New York State Cardiac Registry , 423–424
Ng, K.F.J. , 331
Niemi, T. , 350
Noncardiac complications
AKI ( see Acute kidney injury (AKI))
infectious complications
BSIs ( see Bloodstream infections
(BSIs))
SSIs ( see Surgical site infections
(SSIs))
sternal wound infections , 320–321
respiratory complications
pneumonia ( see Pneumonia)
prolonged intubation and extubation ,
214–215
tracheostomy , 215–216
Noninvasive blood pressure (NIBP)
monitoring
automated blood pressure monitoring
compartment syndrome , 79–80
oscillometric technique , 79
Riva-Rocci/Korotkoff technique , 78–79
Nonsteroidal anti-infl ammatory drugs
(NSAIDs) , 265
acute renal ischemia , 274
adjuvant analgesics , 274
gastrointestinal complications , 274
multimodal analgesia , 265, 276
paracetamol , 265, 274–275
PCA , 265, 276–277
pharmaceutical agents
gabapentin/pregabalin , 265, 276
ketamine , 265, 275
magnesium sulfate (MgSO
4
) ,
265, 275
risk of bleeding , 274
selective COX-2 inhibitors , 273
traditional COX-1 inhibitors , 274
Norepinephrine , 44, 47, 199, 203, 204
Northern New England Cardiovascular
Disease Study Group , 424
NSAIDs. See Nonsteroidal anti-infl ammatory
drugs (NSAIDs)
Nuevo, F.R. , 330
O
Observer’s Assessment of Alertness/Sedation
Scale (OAA/S) , 132
Off-pump coronary artery bypass (OPCAB) ,
305–306, 364
Olanzapine , 67
Olsson, J. , 329
Opioids , 265
body homeostasis
cardiovascular system , 268
cell growth and cell death , 269
Index
https://t.me/med1917
437
extrahypothalamic brain stress system ,
266
gastrointestinal tract , 268
gold standard , 267
HPA , 266
hydrophilic opioids , 267
immune system , 268
morphine , 267
respiratory system , 267–268
side effects of , 269
urinary retention , 269
clinical administration of , 266
compounds
morphine , 269
synthetic opioid agents ( see Synthetic
opioid agents)
receptors , 266
Oral anticoagulants
apixaban , 164, 165
dabigatran , 163–165
rivaroxaban , 164, 165
warfarin , 163, 166
Oral antihypertensive agents , 53–55
Oscillometric technique , 79
P
PAC. See Pulmonary artery catheter (PAC)
Pain management. See Acute postoperative
pain management
Palumbo, D. , 350
Paracetamol , 265, 274–275
Parenteral anticoagulants
DTIs , 164, 168, 169
fondaparinux , 164, 168
LMWH , 164, 167
UFH , 164, 167
Partial carbon dioxide (CO
2
) rebreathing
technology , 107–108
Patient-controlled analgesia (PCA) ,
265, 276–277
Pharmacoeconomics
cost-effectiveness analysis , 74
cost minimization analysis , 74
cost–utility analysis , 74
direct costs , 73
fl uid therapy, cost–benefi t analysis , 74–76
indirect and intangible costs , 74
natural and utility units , 74
Pharmacologic agents
analgesic agents , 50, 59–61
antibiotic prophylaxis , 42–43
drug shortages , 69–70
ICU patients
delirium , 66–67
hyperglycemia , 67–68
inotropic agents , 48–49
intravenous antiarrhythmic agents ,
50, 56–58
medication reconciliation , 68
neuromuscular blocking agents , 64–66
sedating agents , 59, 62–63
stress ulcer prophylaxis , 68–69
vasoactive agents ( see Vasopressor agents)
vasodilators and antihypertensives , 49–55
Phenylephrine , 45, 47, 199, 204
Phosphodiesterase (PDE) inhibitors , 48
PMI. See Postoperative myocardial ischemia
(PMI)
Pneumonia
aspiration , 216–217
lung abscess , 217
postoperative pneumonia
diagnosis , 217–218, 220
management , 219
prognosis , 219
treatment , 218–219
VAP , 220–222
Pneumonia Severity Index , 219
Polderman, K. , 325
Positron emission tomography (PET) , 150
Posterior descending artery (PDA) , 8–10
Posterior tibialis artery cannulation , 85
Postoperative bleeding
antifi brinolytics , 178–179
antiplatelet therapy , 169–171
coagulation status , 170, 172–174
desmopressin , 179
disseminated intravascular coagulopathy ,
175–176
drug-induced thrombocytopenia ,
176–177
exogenous blood products and factors ,
179, 180
fi sh oil , 170
hemodilution , 162
herbal supplements , 170
HIT ( see Heparin-induced
thrombocytopenia (HIT))
oral anticoagulants , 164–166
parenteral anticoagulants , 164, 167–169
protamine , 175
prothrombotic coagulopathies , 175–176
surgical bleeding , 179, 181
Postoperative cardiac tamponade (POCT) ,
204–205
Postoperative myocardial ischemia (PMI) ,
199–200
Index
https://t.me/med1917
438
Postoperative rhythm disorders
bradyarrhythmias , 241–242
supraventricular arrhythmias
incidence and prognosis , 234, 235
management , 237–238
pathogenesis , 235–236
prophylaxis , 236–237
ventricular arrhythmias
incidence and prognosis , 239, 240
management , 239–241
pathogenesis , 239
prophylaxis , 239
Prasugrel , 170, 171
Propofol , 63, 214, 252
Protamine , 164, 167, 175, 299, 370
Prothrombotic coagulopathies , 175–176
Proton pump inhibitor (PPI) , 69, 164, 169, 170
Pulmonary artery catheter (PAC)
clinical outcome of , 98
complications , 103–104
contraindications of , 99
indications for , 99
online cardiovascular monitoring , 98
technical considerations for , 99–103
Pulmonary artery occluding pressure
(PAOP) , 103
Pulmonary artery wedge pressure (PAWP) ,
103, 113
Pulse contour analysis (PCA) , 106, 109–110
Q
Quality-adjusted life year (QALY) , 74
Quetiapine , 67
R
Radial artery cannulation , 82–83
Ramsay Sedation Scale (Ramsay) , 59, 132
RASS. See Richmond Agitation-Sedation
Scale (RASS)
Reid, F. , 326
Remifentanil , 270, 272–273
Renal-dose dopamine , 44, 45
Renin–angiotensin–aldosterone (RAA)
system , 318, 320–322
Respiratory acidosis , 388, 399–401, 404,
409–411
Respiratory alkalosis , 395, 399–401, 404, 411
Reuter, D.A. , 361
Richmond Agitation-Sedation Scale
(RASS) , 59, 132–133
Richter, H. , 29
Right atrial pressure (RAP) , 90, 113
Right coronary artery (RCA) , 8–10
Right internal jugular vein approach , 90–93
Risk-adjustment methodology
data collection , 418–419
multivariable logistic regression model ,
419
over fi tting , 420
risk model assessment
Hosmer–Lemeshow test , 420, 421
model discrimination , 420, 421
model validation , 421
surgeon-specifi c outcomes
observed-to-expected (O/E) ratio , 422
risk-adjusted rates , 422
Riva-Rocci, S. , 78
Rivaroxaban , 164, 165
Russell, J.A. , 335
Ruttmann, T.G. , 331
S
Sarcomere proteins , 24
functional classifi cation of , 19
structural classifi cation of
thick fi lament , 19–22
thin fi lament , 19, 22–23
Scharbert, G. , 345
Schell, R.M. , 146, 147
Sedating agents
consequences of , 59
dexmedetomidine , 62
lorazepam , 62
midazolam , 63
propofol , 63
validated ICU sedation scales , 59
Sedation-Agitation Scale (SAS) , 59, 133
Sedation Intensive Care Score (SEDIC) , 132
Seldinger method , 82
Sertürner, F. , 266
Sessler, C.N. , 132, 133
Shaaban Ali, M. , 144
Singer , 388
Society of Thoracic Surgeons (STS) ,
199, 424, 425
Somatosensory-evoked potential (SSEP) ,
131, 141
Spinal (intrathecal) analgesia , 280–281
SSIs. See Surgical site infections (SSIs)
Starling, E. , 26
Starling equation , 321, 322, 324
Sternal wound infections , 181, 320–321
Stewart-Hamilton equation , 107
Stewart, P. , 389
Stogermuller, B. , 345
Index
https://t.me/med1917
439
Stress ulcer prophylaxis (SUP) , 68–69
Subclavian approach , 93–94, 97
Sufentanil , 270–272
SUP. See Stress ulcer prophylaxis (SUP)
Superfi cial temporal artery , 85
Supraventricular arrhythmias
incidence and prognosis , 234, 235
management , 237–238
pathogenesis , 235–236
prophylaxis , 236–237
Surgical Care Improvement Project , 43
Surgical site infections (SSIs)
diagnosis , 226
intensive care unit , 224
mediastinitis , 225
risk factors for , 225–226
signs and symptoms , 226
treatment , 227
types of , 224, 225
Swan-Ganz catheter. See Pulmonary artery
catheter (PAC)
Swan, H.J. , 98
Synthetic/artifi cial colloids
biological, nonhuman molecules , 336
dextrans , 337–338
gelatins , 338–339
hydroxyethyl starches (HES) ( see
Hydroxyethyl starches (HES))
therapeutic and side effects , 336
Synthetic opioid agents
alfentanil , 272
CSHL , 270
fentanyl , 270–271
remifentanil , 272–273
sufentanil , 271–272
Systemic vascular resistance (SVR) , 26, 46,
81, 114, 199, 203
T
TEA. See Thoracic epidural analgesia (TEA)
TEE. See Transesophageal echocardiography
(TEE)
Thermal diffusion fl owmetry , 151
Thoracic epidural analgesia (TEA) , 281–283
Thoracic paravertebral block , 278–280
Thrombocytopenias. See Heparin-induced
thrombocytopenia (HIT)
Thromboelastography , 170, 173, 174
Ticagrelor , 170, 171
Tirofi ban , 170, 171, 177
Tissue trauma , 93, 95, 96
Tobias, M.D. , 336
Tracheostomy , 215–216, 220
Tranexamic acid (TA) , 178–179
Transcranial Doppler (TCD) , 131, 147–150, 253
Transesophageal echocardiography (TEE) ,
98, 114, 202, 204, 304
Transverse tubules , 14, 15
Tropomodulin , 19, 23, 24
Tropomyosin (TM) , 19, 20, 22–24
Troponin , 19, 23, 200
U
Ulnar artery cannulation , 85
Ultrasonic cardiac output monitor (USCOM) ,
106, 111–112
Ultrasound-guided CVC insertion , 94–95
Unfractionated heparin (UFH) , 164, 167, 183,
184, 299
V
VA. See Ventricular arrhythmias (VA)
Valsalva maneuver , 30
Vancomycin , 43, 177, 229
Vancouver Interaction and Calmness Scale
(VICS) , 59, 132
Van den Berg, B. , 325
Van der Linden, P.J. , 350
VA P . See Ventilator-associated pneumonia
(VAP)
Vascular injuries , 95–96
Vasodilators , 49–52
Vasoplegic syndrome , 203–204
Vasopressin , 45–47, 58, 204
Vasopressor agents , 47
dopamine , 44–45
epinephrine , 46
hypotension , 46
norepinephrine , 44
phenylephrine , 45
reduced systemic vascular resistance , 46
vasopressin , 45
Vennari, M. , 73–76, 313–372, 385–412
Ventilator-associated pneumonia (VAP) , 220
diagnosis , 218, 220
nosocomial infection , 220
postoperative management , 221
treatment and prognosis , 220–221
Ventricular arrhythmias (VA)
incidence and prognosis , 239, 240
management , 239–241
pathogenesis , 239
prophylaxis , 239
Ventricular assist device (VAD) , 208
Verheij, J. , 349
Index
https://t.me/med1917
440
Veterans Administration Database , 424
Visual-evoked potential (VEP) , 141
Vitamin E , 170
von Bezold, A. , 29
W
Wade, C.E. , 332
Warfarin , 163, 166, 185, 190
Warkentin, T.E. , 187
White, H. , 146, 147
Windkessel model , 109
Wyatt, R. , 279
Z
Zheng, F. , 142
Ziprasidone , 67
Index
https://t.me/med1917
Соседние файлы в папке Библиотека им академика М.И. Перельмана